L

Liquidia

Clinical-stage biopharma developing PRINT-based therapeutics

Overview

Liquidia uses PRINT particle engineering to design drug particles that can improve safety, efficacy, and manufacturability. Its two main candidates are LIQ861 for pulmonary arterial hypertension and LIQ865 for local post-operative pain, developed through clinical testing toward commercialization. The technology controls particle size and properties to enhance delivery and performance while aiming to reduce production complexity and cost. By tailoring particle delivery for specific conditions, Liquidia pursues regulatory approvals to bring products to market and generates revenue from sales, supported by stock offerings for funding.

Work here?Claim your company

About Liquidia

Simplify's Rating
Why Liquidia is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Morrisville, NC

Founded

2004

Get referred to Liquidia

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • November 10, 2026 sales rose 31% sequentially, while October shipments hit record highs.
  • Settlement ended litigation uncertainty, removing a major overhang after the September 30 ruling.
  • Cash of $396.1 million and strong YUTREPIA margins fund trials without dilutive financing.

What critics are saying

  • United Therapeutics settlement forces $380.7 million payments through April 2027, crushing flexibility.
  • Liquidia must remove PH-ILD from YUTREPIA labeling, shrinking addressable demand immediately.
  • L606 depends on 2028 enrollment and 2029 submission; any setback delays the next growth engine.

What makes Liquidia unique

  • PRINT technology gives YUTREPIA engineered treprostinil particles and portable dry-powder delivery.
  • YUTREPIA reached $222.7 million quarterly sales by November 10, 2026, proving commercial traction.
  • Liquidia controls inhaled treprostinil sequencing across PAH, PH-ILD, Raynaud’s, and COPD programs.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$522.9M

Above

Industry Average

Funded Over

18 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short-Term Disability
  • Long-Term Disability
  • Employee Stock Purchase Plan
  • Unlimited Paid Time Off

Stock Price

Growth & Insights and Company News

6 month growth

14%

1 year growth

50%

2 year growth

85%
Yahoo Finance
Nov 10th, 2026
Liquidia's YUTREPIA sales jump 31% to $222.7M as $389.7M settlement drives $236.3M loss

Liquidia's third-quarter sales of its pulmonary arterial hypertension drug YUTREPIA rose 31% from the previous quarter to $222.7 million, as the company moved past a patent settlement with United Therapeutics. The company reported a $236.3 million net loss, including a one-time settlement charge of $389.7 million. Of that, $380.7 million is payable through April 2027. Liquidia said it does not need to raise capital and will owe United Therapeutics no ongoing payments after the final one. October shipments hit their highest level since launch. Conversion rates stayed above 87%. Liquidia plans pivotal studies of its L606 formulation, with a regulatory submission targeted for 2029.

The Manila Times
Nov 10th, 2026
Liquidia Corporation to present at 2026 Jefferies Global Healthcare Conference.

Liquidia Corporation to present at 2026 Jefferies Global Healthcare Conference. By GlobeNewswire November 10, 2026 MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) - Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the 2026 Jefferies Global Healthcare Conference,Tuesday, November 17, at 10 a.m. ET/3 p.m. BT in London. Access to these events will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT(R) Technology. PRINT enabled the creation of YUTREPIA(R)(treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To learn more about Liquidia, please visit www.liquidia.com. Contact Information Investors: Jason Adair ADVERTISING Chief Business Officer 919.328.4350

The Lincolnian Online
Nov 10th, 2026
Liquidia (NASDAQ:LQDA) announces earnings results.

Liquidia (NASDAQ:LQDA) announces earnings results. Liquidia (NASDAQ:LQDA - Get Free Report) released its earnings results on Tuesday. The company reported ($2.64) EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($3.60), FiscalAI reports. The business had revenue of $225.30 million for the quarter, compared to analyst estimates of $214.18 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. Liquidia's revenue was up 314.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) EPS. Here are the key takeaways from Liquidia's conference call: * YUTREPIA continued its strong launch growth: third-quarter net product sales rose 31% sequentially to $222.7 million, and adjusted EBITDA reached $140.5 million, its fifth consecutive quarterly increase. The company said more than 70% of September prescriptions included a PAH diagnosis and October shipments were the highest since launch. * The settlement ended the litigation overhang and, according to Liquidia, requires no switch for existing PH-ILD patients; the company reported no changes to payer formularies or coverage. Liquidia said it has no ongoing royalty or payment obligations to United Therapeutics after its final settlement payment in April 2027. * Management said litigation-related uncertainty briefly slowed referrals at some centers: October's daily referral rate was more than 75% of Q3's rate. Liquidia expects referrals to recover but said it wants more data before providing 2027 revenue guidance, which it expects to address in early January. * Liquidia reported a substantial cash balance and said it can fund its plans without raising capital: cash and equivalents were $396.1 million at quarter-end before settlement payments. The GAAP net loss of $236.3 million included a one-time $389.7 million settlement charge, with $380.7 million payable in cash through April 2027. * The company outlined a broad development agenda, including a PH-ILD pivotal study for L606 expected to complete enrollment in 2028, with data intended to support an NDA submission in 2029; a PAH pivotal study is planned for 2027. It also expects to complete its YUTREPIA Raynaud's dose-finding study in the first half of 2027 and plans a PH-COPD pivotal study in the second half of 2027. Liquidia trading down 1.0%. NASDAQ:LQDA traded down $0.49 during trading hours on Tuesday, hitting $47.38. The stock had a trading volume of 987,698 shares, compared to its average volume of 2,282,903. Liquidia has a one year low of $22.31 and a one year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a market cap of $4.24 billion, a price-to-earnings ratio of 34.58, a P/E/G ratio of 0.41 and a beta of 0.40. The business's 50 day moving average is $49.99 and its 200-day moving average is $54.47. Insider buying and selling. In related news, insider Jason Adair sold 688 shares of the company's stock in a transaction on Monday, October 26th. The shares were sold at an average price of $43.19, for a total value of $29,714.72. Following the completion of the sale, the insider owned 177,269 shares in the company, valued at $7,656,248.11. This represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Scott Moomaw sold 8,863 shares of the company's stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $252,418.24. Following the completion of the sale, the insider owned 181,487 shares of the company's stock, valued at approximately $5,168,749.76. This represents a 4.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 566,579 shares of company stock valued at $25,746,120. 25.60% of the stock is owned by company insiders. Wall Street analyst weigh in. Several research firms have recently issued reports on LQDA. Wall Street Zen lowered Liquidia from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. Bank of America upped their price objective on Liquidia from $79.00 to $92.00 and gave the company a "neutral" rating in a report on Thursday, August 13th. Jefferies Financial Group upgraded Liquidia to a "strong-buy" rating in a report on Thursday, October 1st. Weiss Ratings raised Liquidia from a "sell (d-)" rating to a "hold (c)" rating in a research note on Tuesday, September 22nd. Finally, Wedbush set a $58.00 target price on Liquidia in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Liquidia has an average rating of "Hold" and a consensus target price of $72.85. Liquidia company profile. Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company's marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil. Liquidia was founded in 2004 and uses its PRINT particle-engineering technology in drug development. Further reading. Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.

Yahoo Finance
Nov 10th, 2026
Liquidia's Yutrepia sales hit $222.7M in Q3, but $389.7M settlement drives $236.3M net loss

Liquidia reported third-quarter 2026 net sales of $222.7 million for its pulmonary arterial hypertension drug YUTREPIA, up 31% from the second quarter. October patient shipments hit their highest monthly level since launch. The company posted a net loss of $236.3 million, which includes a $389.7 million charge from settling all litigation with United Therapeutics. Adjusted EBITDA rose for the fifth straight quarter, to $140.5 million. Under the October 13 settlement, Liquidia will pay a net $380.7 million in instalments across 2026 and 2027. It plans to fund this from cash and YUTREPIA sales, and has agreed to drop the drug's PH-ILD indication. Cash and cash equivalents stood at $396.1 million on September 30, before settlement payments.

MarketBeat
Nov 10th, 2026
Liquidia Q3 earnings call highlights.

Liquidia Q3 earnings call highlights. November 10, 2026 Key points. * YUTREPIA sales rose 31% sequentially in Q3, with more than 70% of prescriptions in September including a PAH diagnosis. October shipments hit a post-launch high, while new referrals remained above 75% of the Q3 daily rate and conversion rates exceeded 87%. * Liquidia reported a $236.3 million GAAP net loss, including a $389.7 million one-time settlement charge; $380.7 million is payable through April 2027. The company said it does not need to raise capital and will not owe United Therapeutics ongoing payments after the final settlement payment. * Liquidia plans to advance studies of YUTREPIA and its investigational L606 formulation, with pivotal L606 studies planned in PAH and PH-ILD and a regulatory submission targeted for 2029. It also plans a pivotal L606 study in pulmonary hypertension associated with COPD in the second half of 2027. * Interested in Liquidia? Here are five stocks we like better. Liquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics. YUTREPIA net product sales rose to $222.7 million from the second quarter, including $212.2 million in paid patient demand sales. Liquidia reported a $236.3 million net loss under generally accepted accounting principles, reflecting a $389.7 million one-time settlement charge. Chief Executive Officer Roger Jeffs said the settlement ended litigation uncertainty surrounding YUTREPIA and that the company would focus on its business and development pipeline. The drug is indicated for pulmonary arterial hypertension, or PAH, while patients already receiving it for pulmonary hypertension associated with interstitial lung disease, known as PH-ILD, are not required by the settlement to switch treatments, he said. Referrals and prescribing after settlement. Jeffs said more than 60% of YUTREPIA prescriptions from launch through September included a PAH diagnosis, rising to more than 70% in September. Total monthly shipments to patients reached their highest level since launch in October, the first full month after the recent court ruling, he said. New referrals held up despite uncertainty, Jeffs said. The daily referral rate in October was more than 75% of the third-quarter daily rate. He attributed a pause at some treatment centers partly to a competitor's letter to health care providers following the ruling and said he expects referrals to recover after Liquidia communicated with prescribers about the settlement. Liquidia had approximately 1,300 YUTREPIA prescribers. Roughly 60% had prescribed the drug for at least two patients, and more than 30% had prescribed it for at least five, Jeffs said. He added that conversion rates remained above 87%, with no change in formulary status or coverage. Chief Commercial Officer Scott Moomaw said the physician attestation required under the settlement takes the form of a checkbox on the prescription intake form. Chief Operating Officer and Chief Financial Officer Michael Kaseta said the company did not expect changes to patient reauthorizations, although he acknowledged a limited impact was theoretically possible. Settlement charge and financial outlook. Of the $389.7 million settlement charge, $380.7 million is payable in cash through April 2027, Kaseta said. Liquidia ended the third quarter with $396.1 million in cash and cash equivalents before the settlement payments, up $111.9 million from the prior quarter. Discover more MarketBeat All Access MarketBeat Portfolio Tracker MarketBeat Research Tools Adjusted earnings before interest, taxes, depreciation and amortization, a non-GAAP measure, rose to $140.5 million, marking a fifth consecutive quarterly increase. Gross margin was approximately 94%, similar to the second quarter. Research and development expenses rose 47% sequentially to $25.3 million as enrollment increased in the RE-SPIRE study and new YUTREPIA studies began. Kaseta said Liquidia does not need to raise capital and is not changing its operating plan. He said there would be no royalties or ongoing payments to United Therapeutics after the final settlement payment. Asked about an earlier settlement proposal, Jeffs said United Therapeutics had sought 100% of PH-ILD revenue through 2042 and 50% of PAH revenue. He characterized the offer as unreasonable. The call did not include a response from United Therapeutics. Kaseta said Liquidia wanted more data before issuing 2027 revenue guidance and expected to provide more information in early January, when the company also plans to share fourth-quarter results. Clinical development plans. Liquidia plans to continue studies of YUTREPIA dosing flexibility in PAH. Chief Medical Officer Rajeev Saggar said the open-label SPRINT study, expected to initiate at the end of 2026, will compare three-times-daily and four-times-daily dosing and aims to measure a 20% to 25% reduction in pulmonary vascular resistance. The company also plans to launch a real-world PAH registry called EASY-PAH in 2027. For L606, an extended-release liposomal formulation of treprostinil delivered by nebulizer, the global pivotal RE-SPIRE study in PH-ILD is expected to complete enrollment in 2028. A separate pivotal PAH study, AMPLIFY-PAH, is planned to start in 2027. Jeffs said the studies are expected to support a regulatory submission in 2029. Liquidia also plans a pivotal L606 study in pulmonary hypertension associated with chronic obstructive pulmonary disease in the second half of 2027. Saggar said the company believes the formulation could reduce upper respiratory irritation, while noting that an earlier study of another inhaled treprostinil product in that population was stopped for safety reasons. Separately, Liquidia is enrolling patients in RE-WARM, a YUTREPIA dose-finding study in systemic sclerosis associated with Raynaud's phenomenon. Jeffs said the study is expected to finish in the first half of 2027 and, if successful, could support a pivotal study during subsequent winter seasons. About Liquidia (NASDAQ:LQDA). Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company's marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Liquidia, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list. While Liquidia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat

Recently Posted Jobs

Sign up to get curated job recommendations

Liquidia is Hiring for 20 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs